Drug intelligence / Profile preview

SAR444336

Development stage: Phase 2
Lead developer: Sanofi
Modality: Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
Administration: Subcutaneous

Overview

SAR444336 is a site-specific, covalently-bound, monopegylated interleukin-2 (IL-2) engineered "Synthorin" developed using Expanded Genetic Alphabet platform technology. This approach expands the genetic code to create optimized biologics with improved properties. SAR444336 is designed as a non-beta IL-2 variant that selectively stimulates regulatory T cells (Tregs) by increasing reliance on the IL-2 receptor alpha chain subunit (CD25), thereby promoting immune tolerance and reducing inflammatory and autoimmune responses. Preclinical studies have shown that it can expand antigen-specific Tregs while limiting proliferation of NK and CD8+ T cells, making it an attractive candidate for controlling autoimmunity and inflammation. The drug is administered subcutaneously and is currently in Phase I clinical development for inflammatory diseases.

Other names: Pegylated IL2 (Sanofi)

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on SAR444336.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR444336.

Explore the full profile